MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.msard.2023.104564

Медицинская библиотека · Multiple sclerosis and related disorders · 2023

Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.

Fakih Ali Ussama, Sahraian Mohammad Ali, Paybast Sepideh, Naser Moghadasi Abdorreza

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Natalizumab and fingolimod are well-established, sequestrating disease-modifying treatments (DMTs), widely used as a second-line treatment in patients with relapse remitting multiple sclerosis (RRMS). However, there is no standard strategy for managing treatment failure on these agents. The present study aimed to evaluate the effectiveness of rituximab after natalizumab and fingolimod withdrawal.

METHODS

A retrospective cohort was accomplished on RRMS patients treated with natalizumab and fingolimod who were switched to rituximab.

RESULTS

100 patients (50 cases in each group) were analyzed. After six months of follow-up, a substantial decline in clinical relapse and disability progression was observed in both groups. However, no significant change was demonstrated in the pattern of MRI activity (P = 1.000) in natalizumab pretreated patients. After adjusting for the baseline characteristics, a head-to-head comparison found a non-significant trend of lower EDSS in the pretreated fingolimod group compared to those previously treated with natalizumab(P = 0.057). However, in terms of clinical relapse and MRI activity, the clinical outcomes were comparable in both groups ((P = 0.194), (P = 0.957). Moreover, rituximab was well-tolerated, and no serious adverse events were reported.

CONCLUSION

The present study revealed the effectiveness of rituximab as an appropriate alternative option for escalation therapy after fingolimod and natalizumab discontinuation.

Для цитирования: Fakih Ali Ussama, Sahraian Mohammad Ali, Paybast Sepideh, Naser Moghadasi Abdorreza. Effectiveness and safety of switching from fingolimod and natalizumab to rituximab in patients with relapsing remitting multiple sclerosis.. Multiple sclerosis and related disorders. 2023. DOI: 10.1016/j.msard.2023.104564.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.